RxDoctor Payments Data

Aditya Chopra, MD

Internal Medicine · Annapolis, MDNPI 1508850991

Payments from drug & device makers

$84,863in general payments, 2019–2025

Across 1,432 payments — averaging $59.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$55K
  • Amgen$5K
  • AstraZeneca$4K
  • GSK$3K
  • Biohaven Pharmaceuticals, Inc.$2K
  • Pfizer$1K
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$1,2001%
  • Speaking & faculty fees$52,00761%
  • Travel & lodging$1,5112%
  • Food & beverage$29,78735%
  • Education$3580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)257$54,767
Amgen(2 entities)148$5,447
AstraZeneca(2 entities)118$3,512
GSK132$3,291
Biohaven Pharmaceuticals, Inc.18$1,721
Pfizer68$1,222
Novo Nordisk72$1,136
Lilly USA, LLC48$930
Astellas Pharma US Inc28$809
Otsuka America Pharmaceutical, Inc.30$760
Sumitomo Pharma America, Inc.22$616
Boehringer Ingelheim32$615
Bayer29$607
Phathom Pharmaceuticals, Inc.18$428
Biogen18$416
Johnson & Johnson18$397
Kowa Pharmaceuticals America, Inc.28$393
Sunovion Pharmaceuticals Inc.25$392
Esperion Therapeutics, Inc.13$377
Amarin Pharma, Inc.20$374
Biohaven Pharmaceutical Holding Company Ltd.12$335
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$333
Novartis18$331
Merck15$304
Axsome Therapeutics, Inc.10$294
Harmony Biosciences LLC7$293
Acadia Pharmaceuticals Inc14$283
Corcept Therapeutics12$282
Silk Road Medical, Inc.5$255
Corium, LLC7$253
Idorsia Pharmaceuticals US Inc6$209
Lundbeck LLC14$205
Abbott10$197
Nevro Corp.5$186
Teva Pharmaceuticals USA, Inc.10$179
Boston Scientific2$159
Eisai Inc.8$153
Daiichi Sankyo Inc.7$133
Urovant Sciences Inc2$125
Xeris Pharmaceuticals, Inc.3$123
Avanir Pharmaceuticals, Inc.7$107
Genentech USA, Inc.6$101
Mylan Specialty L.p.5$101
Endo Pharmaceuticals Inc.5$92
Shield Therapeutics Inc5$90
Medtronic(2 entities)2$84
Amneal Pharmaceuticals LLC5$83
Verona Pharma, Inc.3$75
Arbor Pharmaceuticals, Inc.5$68
Currax Pharmaceuticals LLC4$60
Vanda Pharmaceuticals Inc.2$53
Ironwood Pharmaceuticals, Inc4$53
Optinose US, Inc.2$53
Aytu Biopharma, Inc.3$51
E.r. Squibb & Sons, L.L.C.4$50
Kyowa Kirin, Inc.2$50
Takeda Pharmaceuticals U.S.A., Inc.2$49
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$47
Gilead2$45
Acorda Therapeutics, Inc2$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,863 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$687,740
Medicare patients
576
Services billed
13,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban246$156,274
Trelegy ElliptaFluticasone/Umeclidin/Vilanter167$121,199
JardianceEmpagliflozin136$114,578
NuplazidPimavanserin Tartrate22$101,403
FarxigaDapagliflozin Propanediol128$91,487
TrulicityDulaglutide74$72,265
Breztri AerosphereBudesonide/Glycopyr/Formoterol92$62,742
Janumet XrSitagliptin Phos/Metformin Hcl53$55,733
MyrbetriqMirabegron109$52,442
XareltoRivaroxaban78$42,426
RexultiBrexpiprazole29$37,414
VraylarCariprazine Hcl30$36,726
MounjaroTirzepatide32$34,344
RybelsusSemaglutide17$24,446
LinzessLinaclotide30$22,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$3,512$159,833244 claims
PfizerEliquis$1,222$156,274246 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$3,291$144,204214 claims
Boehringer IngelheimJardiance, Combivent Respimat$615$120,883149 claims
Lilly USA, LLCTrulicity, Mounjaro$930$106,610106 claims
Acadia Pharmaceuticals IncNuplazid$283$101,40322 claims
MerckJanumet Xr, Januvia$304$76,66180 claims
AbbVieVraylar, Linzess, Namzaric$54,767$67,34873 claims
Astellas Pharma US IncMyrbetriq$809$52,442109 claims
Novo NordiskRybelsus, Ozempic$1,136$44,84739 claims
Johnson & JohnsonXarelto$397$42,42678 claims
Otsuka America Pharmaceutical, Inc.Rexulti$760$37,41429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →